Kiora Pharmaceuticals licenses KIO-401 from Senju for $3.5 million upfront
Kiora Pharmaceuticals entered into an exclusive license agreement with Senju Pharmaceutical on October 23, 2026, for the late-stage calpain inhibitor KIO-401, covering territories outside Asia. The deal calls for a $3.5 million upfront payment, a low-teen-million-dollar payment on technology transfer, and up to $168.5 million in milestones, and the company says it is evaluating financing to fund development. For shareholders, the filing adds near-term cash obligations and funding uncertainty, and it reports no revenue or earnings figures.
Key points
- Upfront payment of $3.5 million to Senju, with a further low-teen-million-dollar payment upon technology transfer, a portion of which may be credited against future milestones.
- Up to $168.5 million in additional regulatory and commercial milestone payments, plus single-digit royalties on net sales in the licensed territory.
- Kiora discontinued research and development of KIO-104 and is evaluating financing alternatives to fund KIO-401 development.
- Target initiation of the multinational Phase 3 CRAO trial is 2027, subject to funding and regulatory alignment.
The filing
Written by AI on Nov 9, 2026, 10:08 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on October 29, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.